Some aspects of interindividual variations in the metabolism of xenobiotics

Inflammation Research

Volumn 52, Issue 8, 2003, Pages 322-333

  Tamasi V ^a   Vereczkey, L ^a   Falus, A ^b   Monostory, K ^a  

^a CHEMICAL RESEARCH CENTER   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cytochrome P450 gene; Inducers; Nuclear receptors; Polymorphism; Regulation

Indexed keywords

CELL NUCLEUS RECEPTOR; CYTOCHROME P450;

DIMERIZATION; DNA RESPONSIVE ELEMENT; DRUG METABOLISM; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME STABILITY; ENZYME SYNTHESIS; GENE CONTROL; GENETIC POLYMORPHISM; HUMAN; REVIEW; XENOBIOTIC METABOLISM;

CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION; HUMANS; MODELS, GENETIC; MULTIGENE FAMILY; POLYMORPHISM, GENETIC; VARIATION (GENETICS); XENOBIOTICS;

EID: 0041662013     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-003-1186-4     Document Type: Review

References (94)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Therap 1994; 270: 414-23.
2. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol. 1994; 46 (suppl. 1): 417-24.
3. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
4. Nelson DR. Cytochrome P450 nomenclature. In: Philips IR, Shephard EA, editors. Cytochrome P450 Protocols. Humana Press, Totowa New Jersey, 1998: 15-25.
5. Morgan ET, Sewer MB, Iber H, Gonzalez FJ, Lee Y-H, Tukey RH et al. Physiological and pathophysiological regulation of cytochrome P450. Drug Metab Dispos 1998; 26: 1232-40.
6. Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Therap 2001; 92: 147-63.
7. Morgan ET. Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab Dispos 2001; 29: 207-12.
8. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 2000; 347: 321-37.
9. Corchero J, Pimprale S, Kimura S, Gonzalez FJ. Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics 2001; 11: 1-6.
10. Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 1998; 28: 1129-65.
11. Fujisawa-Sehara A, Sogawa K, Yamane M., Fuji-Kurijama Y. Characterization of xenobiotic responsive elements upstream from the drug-metabolizing cytochrome P-450c gene: a similarity to glucocorticoid regulatory elements. Nucleic Acids Res 1987; 15: 4179-91.
12. Kawajiri K, Hayashi S-I. The CYP1 family. In: Ioannides C, editor. Cytochrome P450: metabolic and clinical aspects. Boca Raton: CRC Press 1996: 77-97.
13. Yanagida A, Sogawa K, Yasumoto K-I, Fujii-Kurijama Y. A novel cis-acting DNA element required for a high level of inducible expression of the rat P-450c gene. Mol Cell Biol 1990; 10: 1470-75.
14. Baba T, Mimura J, Gradin K, Kuroiwa A, Watanabe T, Matsuda Y et al. Structure and expression of the Ah receptor repressor gene. J Biol Chem 2001; 276: 33101-10.
15. Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 1992; 256: 1193-95.
16. Whitelaw M, Pongratz I, Wilhelmsson A, Gustafsson J-A, Poellinger L. Ligand-dependent recruitment of the Arnt coregulator determines DNA recognation by the dioxin receptor. Mol Cell Biol 1993; 13: 2504-14.
17. Matsushita N, Sogawa K, Ema M, Yashida A, Fujii-Kuriyama Y. A factor binding to the xenobiotic responsive element (XRE) of P-4501A1 gene consist of at least two helix-loop-helix proteins, Ah receptor and Arnt. J Biol Chem 1993; 268: 21002-6.
18. Boucher PD, Piechocki MP, Hines RN. Partial characterization of the human CYP1A1 negatively acting transcription factor and mutational analysis of its cognate DNA recognition sequence. Mol Cell Biol 1995; 15: 5144-51.
19. Linder MW, Falkner KC, Sprinivasan G, Hines RN, Prough RA. Role of canonical glucocorticoid responsive elements in modulating expression of genes regulated by the arylhydrocarbon receptor. Drug Metab Rev 1999; 31: 247-71.
20. Monostory K, Vereczkey L. The effect of dexamethasone on in vitro induction of CYP1A1 by 3-methylcholantrene. Microsomes and Drug Oxidations, Stresa, Italy. July 10-14 2000; 104.
21. Fukuda Y, Ishida N, Noguchi T, Kappas A, Sassa S. Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells. Biochem Biophys Res Commun 1992; 184: 960-65.
22. Fukuda Y, Sassa S. Suppression of cytochrome P450IA1 by interleukin-6 in human HepG2 hepatoma cells. Biochem Pharmacol 1994; 47: 1187-95.
23. Abdel-Razzak Z, Corcos L, Fautrel A, Campion JP, Guillouzo A. Transforming growth factor-β1 down-regulates basal and polycyclic aromatic hydrocarbon-induced cytochromes P-450 1A1 and 1A2 in adult human hepatocytes in primary culture. Mol Pharmacol 1994; 46: 1100-10.
24. Muntane-Relat J, Ourlin J-C, Domergue J, Maurel P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2 and CYP3A4 in human hepatocytes in primary culture. Hepatology 1995; 22: 1143-53.
25. Kawajari K, Nakachi K, Imai K, Yoshii A, Shonida N, Watanabe J. Identification of genetically high risk individual to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett 1990; 263: 131-3.
26. Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBridge OW et al. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 1991; 48: 720-5.
27. Anttila S, Tuominen P, Hirvonen A, Nurminen M, Karjalainen A, Hankinson O et al. CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor. Pharmacogenetics 2001; 11: 501-9.
28. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 1991; 110: 407-11.
29. Taioli E, Crofts F, Trachman J, Bayo S, Toniolo P, Garte SJ. Racial differences in CYP1A1 genotype and function. Toxicol Lett 1995; 77: 357-62.
30. Cascorbi I, Brockmöller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996; 56: 4965-9.
31. Hayashi S, Watanabe J, Nakachi K, Eguchi H, Gotoh O, Kawajiri K. Interindividual difference in expression of human Ah receptor and related P450 genes. Carcinogenesis 1994; 15: 801-6.
32. Micka J, Milatovich A, Menon A, Grabowski AG, Puga A, Nebert DW. Human Ah receptor (AHR) gene: localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics 1997; 7: 95-101.
33. Smart J, Daly KA. Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 2000; 10: 11-24.
34. Wong JMY, Okey AB, Harper PA. Human aryl hydrocarbon receptor polymorphisms that result in loss of CYP1A1 induction. Biochem Biophys Res Commun 2001; 288: 990-6.
35. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-27.
36. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413-580.
37. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996; 56: 2979-84.
38. Tang YM, Wo Y-YP, Stewart J, Hawkins AL, Griffin CA, Sutter TR et al. Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J Biol Chem 1996; 271: 28324-30.
39. Shehin SE, Stephenson RO, Greenlee WF. Transcriptional regulation of the human CYP1B1 gene. J Biol Chem 2000; 275: 6770-6.
40. Hoffman SMG, Fernandez-Salguero P, Gonzales FJ, Mohrenweiser HW. Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19. J Mol Evol 1995; 41: 894-900.
41. Fernandez-Salguero P, Hoffman SMG, Cholerton S, Mohrenweiser HW, Raunio H, Rautio A et al. A genetic polimorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995; 57: 651-60.
42. Guillen MI, Donato MT, Jover R, Castell JV, Fabra R, Trullenque R et al. Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes. J Pharmacol Exp Therap 1998; 285: 127-34.
43. Chang TKH, Waxman DJ. The CYP2A subfamily. In: Ioannides C, editor. Cytochromes P450: metabolic and toxicological aspects. Boca Raton: CRC Press 1996: 99-134.
44. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29: 1322-29.
45. Sueyoshi T, Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 2001; 41: 123-43.
46. Ueda A, Hamadeh HK, Webb HK, Yamamoto Y, Sueyoshi T, Afshari CA et al. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol Pharmacol 2002; 61: 1-6.
47. Zelko I, Negishi M. Phenobarbital-elicited activation of nuclear receptor CAR in induction of cytochrome P450 genes. Biochem Biophys Res Commun 2000; 277: 1-6.
48. Pascussi J-M, Gerbal-Chaloin S, Fabre J-M, Maurel P, Vilarem M-J. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol 2000; 58: 1441-50.
49. Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001; 60: 427-31.
50. Drocourt L, Ourlin J-C, Pascussi J-M, Maurel P, Vilarem M-J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 2002; 277: 25125-32.
51. Pascussi J-M, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre J-M, Maurel P et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000; 274: 707-13.
52. Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 1995; 28: 328-32.
53. Richardson TH, Johnson EF. The CYP2C subfamily. In: Ioaunides C, editor. Cytochromes P450: metabolic and toxicological aspects. Boca Raton: CRC Press 1996: 161-81.
54. Ibeanu GC, Goldstein J. Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry 1995; 34: 8028-36.
55. Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmaun LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 2002; 30: 385-90.
56. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7: 51-8.
57. Gerbal-Chaloin S, Pascussi J-M, Pichard-Garcia L, Daujat M, Waechter F, Fabre J-M et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug. Metab Dispos 2001; 29: 242-51.
58. Gerbal-Chaloin S, Daujat M, Pascussi J-M, Pichard-Garcia L, Vilarem M-J, Maurel P. Transcripcional regulation of CYP2C9 gene. J Biol Chem 2002; 277: 209-17.
59. Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Therap 1999, 290: 635-40.
60. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and pseudogene. Am J Hum Genet 1989; 45: 889-904.
61. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
62. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183-7.
63. Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotype in Black Americans. J Clin Invest. 1993; 91:2150-4.
64. Lou YC, Ying L, Bertilsson L, Sjoqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987; 2: 852-3.
65. Jover R, Bort R, Gomez-Lechon MJ, Castell JV. Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett 1998; 431: 227-30.
66. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, de Waziers I. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 1996; 6: 203-11.
67. Hines RN, Luo Z, Cresteil T, Ding X, Prough RA, Fitzpatrick JL et al. Molecular regulation of genes encoding xenobiotic-metabolizing enzymes: mechanisms involving endogenous factors. Drug Metab Dispos 2001; 29: 623-33.
68. Koop DR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 1992; 6: 724-30.
69. Ueno T, Gonzalez FJ. Transcriptional control of the rat hepatic CYP2E1 gene. Mol Cell Biol 1990; 10: 4495-505.
70. Ronis MJJ, Lindros KO, Ingelman-Sundberg M. The CYP2E subfamily. In: Ioaunides C, editor. Cytochromes P450: metabolic and toxicological aspects. Boca Raton: CRC Press 1996: 211-39.
71. Koop DR, Tierney DJ. Multiple mechanisms in the regulation of ethanol inducible cytochrome P450IIE1. BioEssays 1990; 12: 429-35.
72. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier J-C, Corcos L, Turlin B et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44: 707-15.
73. Maurel P. The CYP3 family. In: Ioannides C, editor. Cytochromes P450: metabolic and toxicological aspects. Boca Raton: CRC Press 1996: 241-70.
74. Goodwin B, Redinbo MR, Kliewer SA. Regulation of CYP3A gene transcription by pregnane X receptor. Annu Rev Pharmacol Toxicol 2002; 42: 1-23.
75. Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcripcional activation of CYP3A4 by rifampicin through a distal enchancer module. Mol Pharmacol 1999; 56: 1329-39.
76. Quatrochi LC, Guzelian PS. CYP3A regulation: from pharmacology to nuclear receptors. Drug Metab Dispos 2001; 29: 615-22.
77. Schuetz JD, Schuetz EG, Thottassery JV, Guzelian PS, Strom S, Sun D. Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Mol Pharmacol 1996; 49: 63-72.
78. Pascussi J-M, Drocourt L, Fabre J-M, Maurel P, Vilarem MJ. Dexamethasone induces pregnane X receptor and retinoid X receptor-α expression in human hepatocytes; synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 2000; 58: 361-72.
79. Pascussi J-M, Drocourt L, Gerbal-Chaloin S, Fabre J-M, Maurel P, Vilarem M-J. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Eur J Biochem 2001; 268: 6346-57.
80. 3. Mol Pharmacol 1997; 51: 741-54.
81. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001; 98: 369-74.
82. Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 2001; 98: 3375-80.
83. Staudinger JL, Liu Y, Madan A, Habeebu S, Klaassen CD. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 2001; 29: 1467-72.
84. Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res 2002; 43: 359-64.
85. Beaune PH, Umbenhauer DR, Bork RW, Lloyd RS, Guengerich FP. Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. Proc Natl Acad Sci USA 1986; 83: 8064-68.
86. Bork RW, Muto T, Beaune PH, Srivastava PK, Lloyd RS, Guengerich FP. Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J Biol Chem 1989; 264: 910-19.
87. Gonzalez FJ, Schmid BJ, Umeno M, McBridge OW, Hardwick JP, Meyer UA et al. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 1988; 7: 79-86.
88. Gellner K, Eiselt R, Huster E, Arnold H, Koch I, Haberl M et al. Genomic organisation of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001; 11: 111-21.
89. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30: 1108-14.
90. Jounaidi Y, Hyrailles V, Gervot L, Maurel P. Detection of a CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun 1996; 221: 466-70.
91. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91.
92. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Therap 2002; 300: 355-60.
93. Sarkar MA, Vadlamuri V, Ghosh S, Glover DG. Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during menstrual cycle. Drug Metab Dispos 2003; 31: 1-6.
94. Lake BG, Lewis DFV. The CYP4 family. In: Ioannides C, editor. Cytochromes P450: metabolic and toxicological aspects. Boca Raton: CRC Press 1996: 271-97.